ArticleOncoTargets and therapy2019
Upregulation of STC2 in colorectal cancer and its clinicopathological significance.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Prognostic value of high stanniocalcin 2 expression in solid cancers: A meta-analysis.Medicine · 2019Pooled it
- Predictive Value ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Identification of a metabolic-immune signature associated with prognosis in colon cancer and exploration of potential predictive efficacy of immunotherapy response.Clinical and experimental medicine · 2025Article
- Risk Prediction of Colon Cancer Metastasis and Bioinformatics Analysis of Aspirin Treatment.International journal of genomics · 2025Article
- Stanniocalcin-2 significantly promotes colorectal cancer progression by regulating cancer cell proliferation and invasion.Journal of Cancer · 2025Article
- Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies.Experimental hematology & oncology · 2024Review
- Identifying subtypes and developing prognostic models based on N6-methyladenosine and immune microenvironment related genes in breast cancer.Scientific reports · 2024Article
- Development and validation of a combined hypoxia and ferroptosis prognostic signature for breast cancer.Frontiers in oncology · 2023Article
- The analysis of tumor-infiltrating immune cell and ceRNA networks in laryngeal squamous cell carcinoma.Medicine · 2022Article
- Stanniocalcin 2 drives malignant transformation of human glioblastoma cells by targeting SNAI2 and Matrix Metalloproteinases.Cell death discovery · 2022Article
- Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target.Journal of experimental & clinical cancer research : CR · 2022Review
- Immunohistochemical Expression of Stanniocalcin 2 in Colorectal Cancer: A Retrospective Egyptian Study.Iranian journal of pathology · 2022Article
- Article
- Combined Efficacy of CXCL5, STC2, and CHI3L1 in the Diagnosis of Colorectal Cancer.Journal of oncology · 2022Article
- Exploration of Different Hypoxia Patterns and Construction of a Hypoxia-Related Gene Prognostic Index in Colorectal Cancer.Frontiers in immunology · 2022Article
- A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2).Frontiers in genetics · 2022Review
- Glycometabolism-related gene signature of hepatocellular carcinoma predicts prognosis and guides immunotherapy.Frontiers in cell and developmental biology · 2022Article
- Establishment of a circular RNA regulatory stemness-related gene pair signature for predicting prognosis and therapeutic response in colorectal cancer.Frontiers in immunology · 2022Article
- Exploration and validation of a combined immune and metabolism gene signature for prognosis prediction of colorectal cancer.Frontiers in endocrinology · 2022Article
- The significance of Stanniocalcin 2 in malignancies and mechanisms.Bioengineered · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStanniocalcin 2 (STC2) is a glycoprotein hormone involved in many biological processes and a secretory protein that regulates malignant tumor progression. The aim of the present study was to further explore the clinicopathological significance and prognostic role of STC2 in colorectal cancer (CRC).
methodsIn this study, STC2 expression was first investigated in Gene Expression Omnibus and The Cancer Genome Atlas, and then validated with the data from our medical center. Univariate and multivariate analyses were performed to assess the association between prognostic factors and survival outcome.
resultsIn Gene Expression Omnibus and The Cancer Genome Atlas databases, bioinformatics analysis confirmed that STC2 was significantly increased in CRC compared with that in normal tissues (
conclusionOur results suggested that STC2 played an important role in CRC progression and prognosis, and could be a useful biomarker for survival prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.